{
    "2020-03-24": [
        [
            {
                "time": "2019-03-24",
                "original_text": "复宏汉霖上市首份年报：研发投入14亿元，亏损8.78亿元",
                "features": {
                    "keywords": [
                        "复宏汉霖",
                        "年报",
                        "研发投入",
                        "亏损"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-03-24",
                "original_text": "港股异动丨复星医药涨7.75%控股股东增持计划已累计增持0.28%股份",
                "features": {
                    "keywords": [
                        "复星医药",
                        "港股",
                        "异动",
                        "增持"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-24",
                "original_text": "恒指推出新指数 复星医药（02196）获纳恒生沪深港通生物科技50指数",
                "features": {
                    "keywords": [
                        "恒指",
                        "新指数",
                        "复星医药",
                        "生物科技"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-24",
                "original_text": "复宏汉霖2019年营收同比增11.25倍 汉丽康销售额达7900万元",
                "features": {
                    "keywords": [
                        "复宏汉霖",
                        "营收",
                        "汉丽康",
                        "销售额"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-23",
                "original_text": "【山证医药】医药行业周报（20200323）：海外疫情持续蔓延，建议关注原料药等细分领域",
                "features": {
                    "keywords": [
                        "医药行业",
                        "周报",
                        "海外疫情",
                        "原料药"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "原料药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-03-24",
                "original_text": "恒瑞医药交2019年“成绩单”：营收净利均增长超30% 研发叠加政策助力",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "成绩单",
                        "营收",
                        "净利",
                        "研发",
                        "政策"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}